DS 8273

Drug Profile

DS 8273

Alternative Names: Anti-DR5 monoclonal antibody - Daiichi Sankyo; DS-8273a; DS8273

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Inc
  • Developer Bristol-Myers Squibb; Daiichi Sankyo Inc; New York University School of Medicine
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Malignant melanoma
  • No development reported Lymphoma; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease) in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in USA (IV)
  • 29 Sep 2017 Bristol-Myers Squibb terminates a phase I trial due to business decision in Colorectal cancer (Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease, Combination therapy) in USA (IV) (NCT02991196)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top